Dennis J. Slamon
Linked HER2 amplification to aggressive breast cancer and drove trastuzumab and later palbociclib to approval.
Medical oncologist whose 1987 Science paper tied HER2 amplification to poor prognosis and who led the clinical development of trastuzumab. Later led palbociclib development and the NATALEE adjuvant ribociclib trial.
| Title | Journal | Year |
|---|---|---|
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Science | 1987 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 | New England Journal of Medicine | 2001 |
Pages like this
not linked directly; found by shared links- InstitutionInstituto Alexander Fleming
Shares Palbociclib, CDK4/6, Trastuzumab, HER2.
- PersonSeock-Ah Im
Shares Ribociclib, NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer, Palbociclib, CDK4/6.
- PersonDebu Tripathy
Shares Ribociclib, CDK4/6, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer.
- PersonYeon Hee Park
Shares Palbociclib, CDK4/6, HER2, HER2-positive breast cancer.
- IdeaCDK4-selective inhibitors as the new first-line backbone
Shares Ribociclib, Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.
- InstitutionSOLTI Cancer Research Group
Shares Ribociclib, Palbociclib, Trastuzumab, HER2-positive breast cancer.
- TrialHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)
Shares Barbara Bradfield, Trastuzumab, HER2, HER2-positive breast cancer.
- TrialPALOMA-2
Shares Palbociclib, CDK4/6, HR-positive / HER2-negative breast cancer.